Tafinlar
Novartis’ Tafinlar/Mekinist combo improves five-year relapse-free survival in new Phase 3 data
September 17, 2020Research and Development Novartis, Tafinlar, mekinist, melanoma
Novartis has unveiled promising new Phase 3 data for its combination of Tafinlar (dabrafenib) with Mekinist (trametinib) in the treatment …
NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma
September 17, 2018Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma
NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …
FDA approves Novartis combo in rare thyroid cancer subtype
May 8, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer
The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …
Novartis combo expands into lung cancer with EU approval
April 4, 2017Manufacturing and Production, Sales and Marketing NSCLC, Novartis, Tafinlar, mekinist
Novartis has announced that its Tafinlar (dabrafenib) and Mekinist (trametinib) drug combo has been approved by the European Commission (EC) …
Novartis says Phase II data for rare lung cancer showed overall response rate of 63%
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist
Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …
AstraZeneca lung drug shines on
June 1, 2015Sales and Marketing ASCO, AZD9291, AstraZeneca, MEDI4736, NSCLC, Tafinlar
AstraZeneca’s investigational drug AZD9291 is continuing to impress, with results announced at cancer conference ASCO building on its previous ‘unprecedented’ …
GSK melanoma drug sees quick NICE nod
September 18, 2014Sales and Marketing Cancer, GSK, NICE, Tafinlar, Yervoy, dabrafenib, melanoma, skin cancer
NICE is recommending GlaxoSmithKline’s new melanoma treatment Tafinlar (dabrafenib) after the firm offered a discount for its medicine. In final …
GSK melanoma drugs beat rival in new study
July 18, 2014Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma
GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …
Mekinist shown EU green light
July 7, 2014Sales and Marketing CHMP, Cancer, GSK, Tafinlar, braf, mekinist, melanoma
The European Commission has given GlaxoSmithKline’s melanoma drug Mekinist the thumbs-up following a positive opinion in April from the European …
GSK and Novartis sign multi-billion dollar deal
April 23, 2014Research and Development, Sales and Marketing GSK, Novartis, Tafinlar, lilly, merger, tykerb, vaccines
GlaxoSmithKline and Novartis are radically shaking up their businesses, starting up a joint venture while selling off major parts of …
GSK to make ‘fundamental changes’
February 6, 2014Sales and Marketing China, GSK, Tafinlar, Witty, q4, results
GlaxoSmithKline has pledged to make ‘fundamental changes’ to the manner in which it does business, looking at its interaction with …
Three new entries to Cancer Drugs Fund
February 5, 2014Research and Development, Sales and Marketing CDF, Kadcyla, NHS, Tafinlar, UK, xofigo
Three drugs – Roche’s Kadcyla, Bayer’s Xofigo and GlaxoSmithKline’s Tafinlar – have been added to England’s Cancer Drugs Fund (CDF). …
GSK has Tafinlar ‘breakthrough’
January 15, 2014Sales and Marketing Cancer, FDA, GSK, NSCLC, Tafinlar
GlaxoSmithKline is on a roll, with its cancer drug Tafinlar given breakthrough therapy designation by the FDA in lung cancer …
FDA approves GSK cancer combo
January 14, 2014Research and Development, Sales and Marketing FDA, GSK, Tafinlar, mekinist
US regulators have shown the green light to a combination of two GlaxoSmithKline skin cancer drugs, Mekinist and Tafinlar, to …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
